Please note that the URL for this site has changed to a 'phe.org.uk' address from 'nhs.uk'. This reflects changes we have made to hosting for this site.
 

The UK NSC recommendation on Fetomaternal and Neonatal Alloimmune Thrombocytopenia (FMAIT) screening (currently in consultation)

 

This recommendation is currently being reviewed as part of the UK NSC's regular review cycle of all policies.

The review process began in Mar 2016 and is estimated to be completed by Feb 2017.

» Download the expert review for FMAIT (PDF document, 737KB)

The UK NSC welcomes comments and feedback on the expert review during the consultation period that lasts from 19/09/2016 until 19/12/2016. Please send comments to us by e-mail using this feedback form.

Please note that all consultation submissions will be published on this page when the review is complete. Full details can be found in the confidentiality and disclosure section at the bottom of this page.

Recommendation Systematic population screening programme not recommended
 

Find general information about population health screening.

More about FMAIT

When an unborn baby's platelets (cells necessary for blood clotting) are not recognised by the mother's body, she sometimes makes antibodies which attack the baby's platelets (Fetomaternal alloimmune thrombocytopenia, FMAIT). This causes bleeding in the baby in the womb or shortly after birth. Babies can be at serious risk of brain damage or death.

Stakeholders

BLISS
British Committee for Standards in Haematology (BCSH)
British Paediatric Allergy, Immunology and Infection Group
Brtish Association of Perinatal Medicine
Faculty of Public Health
FortuNAIT
NAIT Babies
NHS Blood & Transplant
Royal College of General Practitioners
Royal College of Midwives
Royal College of Obstetricians and Gynaecologists
Royal College of Paediatrics and Child Health
UK Newborn Screening Laboratories Network

The stakeholder groups will be involved when the recommendation is next reviewed. If you think your organisation should be added, please contact us. More information for stakeholders can be found in appendix C of the UK NSC evidence review process.

Related documents

icon Summary of Policy Recommendation and Consultation responses for FMAIT 250713 (PDF document, 42KB, 26/07/13)

Confidentiality and disclosure

Information provided in response to this consultation, including personal information, may be subject to publication or release to other parties or to disclosure in accordance with the access to information regimes (these are primarily the Freedom of Information Act 2000, the Data Protection Act 1998, and the Environmental Information Regulations 2004). If you want information, including personal data that you provide to be treated as confidential, please be aware that, under the FOIA, there is a statutory Code of Practice with which public authorities must comply and which deals, amongst other things, with obligations of confidence.

In view of this it would be helpful if you could explain to us why you regard the information you have provided as confidential. If we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. An automatic confidentiality disclaimer generated by your IT system will not, of itself, be regarded as binding on the UK National Screening Committee.

Any request for information to be treated in confidence will be taken into consideration in the publication of responses to the consultation. The UK National Screening Committee intends to publish all responses following the closure of the consultation period, however we will not publish responses from respondents who request that any of the information in their response, including personal data, should be handled in confidence. The UK National Screening Committee reserves the right not to publish or take into account any representations which are openly offensive or defamatory.

More options

Go to top